LuMind IDSC signs on to NTG statement re: Aduhelm
“It is unknown to what degree aducanumab (Aduhelm) may help people with Down syndrome, as…
CapetivateJuly 13, 2021
Transitioning Into Adulthood: What to Do When Your Loved One With Down Syndrome Becomes An Adult
July 1, 2021 Fleeing the nest or staying home? What happens when your loved one…
Why Patient Voices Are So Critical to the Development and Initial Approval of New Drugs
June 29, 2021 This blogpost from a former FDA insider on the power of the…
CapetivateJune 29, 2021
Ten Useful Tips to Safely Enjoy the Water with Your Loved One with Down Syndrome
June 28, 2021 As the weather starts to warm up, some of us probably can’t…
CapetivateJune 28, 2021
When a Father Becomes a Superhero
June 17, 2021 We all think of our dads as superheroes, and today at LuMind…
CapetivateJune 17, 2021
FDA Approves Biogen’s Aduhelm, the First New Drug for Alzheimer’s Disease Since 2003
Burlington, MA, June 7, 2021 - Today marks an important milestone in Alzheimer’s disease research with…
CapetivateJune 7, 2021
Family Voices for T21RS Virtual Conference
June 1, 2021 When Jay Nothnagle was born in 1974, he was diagnosed with Down…
CapetivateJune 1, 2021
Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study
May 13, 2021 LuMind IDSC’s Chief Scientific Officer, James Hendrix, and a team of dedicated…
CapetivateMay 13, 2021
